

#### Immuron Commences US Investor Roadshow

**19 August 2015, Melbourne, Australia**: Immuron Limited (ASX:IMC) today wishes to announce that the Company has commenced a US Investor Roadshow where the Company will showcase its technology platform and profile to US investment groups.

This US Roadshow comes off the back of recent market announcements detailing the Company's advances in all product areas of the business, Travelan, NASH, ASH, C-Diff, and now Protectyn.

#### Travelan:

Immuron announced the execution of a 50,000 minimum annual order supply agreement for the Company's flagship product, Travelan with the major US Travel Clinic supplier, Traveler's Supply Inc.

#### NASH and ASH Clinical Trials:

The Company's Clinical Trials are progressing well and have been further bolstered by the Company's recent appointments of SVP of Innovation Dr Dan Peres, and Chief Operating and Scientific Officer Dr Jerry Kanellos.

A recent Deutsche Bank review of the NASH market suggests that there is a worldwide market for NASH of between \$35 - \$40 billion. The high prevalence of Type 2 diabetes and obesity, which lead to NASH and other non-alcoholic fatty liver diseases (NAFLD), boosts the prevalence of NASH and its market growth.

A copy of the US Investor Roadshow Presentation has been attached below.

#### Contacts:

Dr Roger Aston Non-Executive Chairman +61 (0)3 9824 5254 Amanda Loh Buchan Consulting +61 (0)3 9866 4722

#### ABOUT IMMURON

Immuron Ltd (ASX:IMC) is a Microbiom company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The company currently markets Travelan® for the prevention of travellers' diarrhoea, its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH, and it has a preclinical immunotherapy pipeline targeting immune-related diseases with unmet needs.

Immuron's main scientific alliances are with Hadassah Medical Center (Israel), Monash University (Australia) and the Commonwealth Scientific and Industrial Research Organisation (CSIRO) (Australia).

www.immuron.com

## AUGUST 2015

# Immur@n

# ORAL IMMUNOTHERAPY HEALTH TO CHEW ON

A Micro biome Company delivering Oral Immunotherapy for the treatment and prevention of disease. OVERVIEW

## Immur@n

## Forward-looking Statement

Certain statements made in this presentation are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements.

Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements.

The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

Immuron Investor Presentation

NASH/ASH



## **Investment Highlights**

Immuron presents the large upside Investor Potential of a biotech company.

It has a unique natural immune-technology platform with GRAS status that significantly reduces the research to product cycle timelines.

Immuron has a revenue-generating product with multiple revenue pathways

Immuron Investor Presentation

July 2015

3



## Investment Highlights

- NASH: Two Phase II studies in progress with
- ASH: an increasingly alluring potential upside
- Travelan: Revenues growing and positioned to grow further with successful USA launch
- Pipeline: Progressing and Strong
- Cap Pofile: Robust
- Financials: Debt free, cash in the bank until after completion of NASH trial

Immuron Investor Presentation

PIPELINE

# Immur@n

## Capital Structure

#### Market Cap at July 2015 only AUD\$19.5M

ASX Code: IMC	Shares	Listed Options	Unlisted Options
Securities currently on issue	~75M	~3M	~ 6M

#### **Current Top 20 Shareholders**

Rank	Shareholder Name	Qty Held	% Ownership
1	GRANDLODGE PTY LTD	6,290,678	8.39%
2	AUTHENTICS AUSTRALIA PTY LTD	4,999,999	6.67%
3	CHIMAERA CAPITAL LIMITED	3,635,169	4.85%
4	MR PETER ANASTASIOU &	2,907,236	3.88%
5	ADVANCE PUBLICITY PTY LTD	2,100,472	2.80%
6	FIFTY-FIFTH LEPRECHAUN PTY LTD	2,035,371	2.72%
7	MRS JACLYN STOJANOVSKI &	1,974,807	2.63%
8	INSYNC INVESTMENTS PTY LTD	1,534,432	2.05%
9	HADASIT MEDICAL RESEARCH	1,479,102	1.97%
10	MR DAVID ANTHONY PLUSH &	1,334,075	1.78%
11	MR KENNETH BIDDICK &	1,249,999	1.67%
12	G & N LORD SUPERANNUATION PTY	1,237,994	1.65%
13	MR DALE ANTHONY REED	1,200,000	1.60%
14	JOJO ENTERPRISES PTY LTD	918,898	1.23%
15	MR IAN DAVID PATTISON &	657,674	0.88%
16	CAPITAL CONCERNS PTY LIMITED	654,716	0.87%
17	SOMNUS PTY LTD	625,000	0.83%
18	MR HAMISH SALMON &	575,000	0.77%
19	T E & J PASIAS PL	560,000	0.75%
20	ADVANCE CLINICAL SYSTEMS	546,074	0.73%
	TOTAL OF TOP 20 SHAREHOLDERS	36,517,496	48.71%
	Balance of Remaining Shareholders (1,161 Holders)	38,446,736	51.29%
	TOTAL SHARES ON ISSUE (1,181 Holders)	74,964,232	100.00%

Immuron Investor Presentation

5




## What do we do?

Targeting the human immune system with natural antibodies derived from bovine to address diseases of the gut and liver.

#### Why?

Acute and chronic infections in the gut have a major impact in human health, causing dis biosis and many metabolic diseases.





## Unique Platform Technology


NASH

✓ Attractive risk-reward ratio – biotech upside with reduced risk profile

Immuron's Platform Products	Other Products
✓ Natural product	<ul> <li>Synthetic product</li> </ul>
<ul> <li>High safety profile</li> </ul>	Side effects occur
<ul> <li>Not a binary outcome.</li> <li>If clinical end points not attained, there may still be a product that generates revenue</li> </ul>	Binary outcome: clinical trial failure means there is no product
✓ Low Cost	Antibodies typically very expensive to make

Immuron Investor Presentation

# OVERVIEW TRAVELAN NASH PIPELINE SUMMARY Pathway with reduced risk





## 2. TRAVELAN<sup>®</sup> Stop it before it starts

NASH

# Immur@n

#### Travelan<sup>®</sup> - a Unique Preventative Product



# The only therapy that prevents travellers' diarrhoea by up to 90%\*

Without Travelan®: Bacteria attach to gut wall and infect



With Travelan<sup>®</sup>: Bacteria neutralized by Travelan<sup>®</sup> antibodies



10

Immuron Investor Presentation

#### OVERVIEW

NASH

# Immur@n

## Travelan®

#### http://www.travelan.com.au







All-natural product; clinically proven with very high safety profile



Available over-the-counter




Strong brand loyalty

#### 11

Immuron Investor Presentation







\*\* Note: first non-exclusive distribution contract signed for 50,000 units in July 2015 with major Traveller's Supply company at full margin.

Immuron Investor

Presentation

13


OVERVIEW	AN	PIPELINE	SUMMARY	IMM	Ur@n
Travelan®					
Stat	us in Nov 2013		> Progres	s in 2015	
Country	Discussions	Term Sheet	Licensed	Regulatory	In Market
Canada					
South Korea					
Other Asian Cou	Intries			<b>→</b>	
US (partnered)				No regulatory proces	s <sup>3</sup> 4
United States (d	irect)				
India			>		
China		$\rightarrow$			


Regulatory application preceding partnering engagement

Immuron AGM Presentation

## 3. NASH/ASH (INFLAMED FATTY LIVER)

# Immur@n







## NASH – How Big is the Opportunity?

#### How Big is the Opportunity?




#### = Estimated \$40B Market in 2025

NASH - The Next Big Global Epidemic in 10 Years? Deutsche Bank, Markets Research, 14 July 2014



### There is also ASH: alocoholic steatohepatitis



My Doctor said "Only one glass of alcohol a day"

....I can live with that.

IMM-124E chosen by NIH from 27 candidates for a phase II study in ASH. Currently recruiting.

## **Current Treatments Available for NASH?**







## Immuron's Solution for ASH and NASH

NASH/ASH

IMM-124E treats the liver and improves insulin resistance, liver function and reduces high cholesterol, by reducing inflammation and fibrosis.

IMM-124E operates only in the gut and does not enter bloodstream

IMM-124E is safe and may be best in class

**Reduces inflammation** 



Indirect action

Prevents bacterial spread

## **2 Phase II trials started and recruiting**

#### NASH- IMMURON FUNDED

#### Phase II trial has begun:

- Over 20 world class sites participating

- First 30 patients randomised or dosed

#### **ASH- NIH FUNDED**


#### Phase II trial has begun:

- Currently Recruiting
- Patients randomised and dosed

**NIH funded,** selected as 1 of 3 (from a possible 27) treatments to be funded by the NIH

22

Immuron Investor Presentation



#### **NASH Sites** – United States



## The Competitive Landscape

#### **Bile Acid**

Shire - LUM-002

Intercept - Obeticholic acid, modified bile acid

Galmed - Aramchol, Conjugate of Fatty acid and Fatty bile acid

NASH is a Spectrum of conditions: Room for many therapies

#### **Anti-fibrotic**

Gilead - Simtuzumab, anti-fibrotic

**Galectin - galectin proteins** 

Anti-Inflammatory + (anti-inflammatory, anti-diabetic, cholesterol control, FFA)

Immuron - Hyperimmune colostrum enriched with Anti-LPS Abs

Conatus - Emricassan, caspase protease inhibitor

Genfit - Peroxisome proliferator - activated receptor alpha





overview travel		PIPELINE	SUMMARY	mmu	
Indication	Research Pr	e-clinical Pha	se I Phase II	Phase III	Market
Traveller's Diarrhea					Contraction of the second seco
NASH (IMM-124E)			>		
ASH (IMM-124E)	* Tria	I funded by NIH			
Clostridium difficile infection		<b>→</b>			
Other Projects: • diabetes • Colitis/Crohn's I • Fibrosis	> Disease				27 Immuron Investor Presentation July 2015

## In the pipeline

- → IMM-529 as therapy for infections due to overuse of antibiotics
  - Clostridium difficile (C.diff): a gut-borne bacteria
    - superbug
    - more than US\$3.2 billion in health care costs each year in the United States
  - IMM-529 under collaboration with Monash University
- $\rightarrow$


 $\rightarrow$ 

 $\rightarrow$ 

Exceptional pre-clinical results to date:

80% prevention

100% cure in mouse model.



Immuron Investor Presentation

# Comparative Values- Nasdag Peers

\* Immuron is significantly undervalued relative to peers listed on NASDAQ who are currently undertaking a Phase II study in NASH

Average Value for these Companies is over \$100 Million

\* Immuron is significantly undervalued relative to its peers listed on NASDAQ that currently have a C-Diff program in place.

Average Value of these companies is over \$200 Million, although several are in Phase II or Phase III clinical trials.

At \$20 Million Immuron represents a strong Value case with Two phase II studies, a C- Diff program, Travelan sales and a strong pipeline and safe platform.



## 5. SUMMARY

OVERVIEW	TRAVELAN®	NASH	PIPELINE SUMMARY	Ur@n			
	Lo	oking	Forward 2015-16				
Travelo	an	1. 2. 3. 4.	<ol> <li>Increase Canadian Travelan revenue</li> <li>Outstanding early Launch in the US</li> </ol>				
Anothe	er Produc	: <b>ts</b> 5.	Launch anti Lps products in Australia				
NASH		6. 7.					
Other		8. 9. 10.	Continue to progress C difficile project Diabetes Colitis and Crohn's	31 Immuron AGM Presentation July 2015			

#### The Board and Management

Dr Roger Aston Chairman

Daniel Pollock Non-Executive Director

Stephen Anastasiou Non-Executive Director

Peter Anastasiou Director

Dan Peres, MD Senior VP of Innovation

Neta Tobis Clinical Director

Dr. Yaron Ilan Medical Officer

Dr. Jerry Kanellos Chief Scientific Officer

Nicky Konstantopolous Development Manager

Reza Moussakhani Manufacturing Quality Director

Roger has more than 20 years of experience in the pharmaceutical and biotech industries. He was the Founding CEO Chief Executive Officer and a Director of Mayne Pharma Group Limited.

Daniel is an internationally experienced lawyer admitted in both Scotland and Australia, with significant commercial expertise in new market entries into overseas markets, distribution agreements and start ups.

Stephen has extensive experience in general management, marketing and strategic planning in the healthcare industry, formerly with KPMG.

Peter Anastasiou was the founder of major shareholder Grandlodge and has had 20 years of successful investment across many sectors. He started his first Bio Tech at age 23, and has a strong philanthropic Portfolio.

Dan had been leading Medical Device and Pharma companies in their clinical stage since 2008. a Physician in origin has years of experience in management and medical development .

With over 7 years' experience of international trial management for small to large pharma and medical device companies as well as working within large CROs (PPD)

Dr. Yaron Ilan, MD, is a Director-Inpatient Medicine Department at Hadassah Medical Center. He holds more than 50 patents and co-authored more than 240 articles.

Jerry has had over 20 years experience in Pharma and Biotech and has a wealth of knowledge and experience in Regulatory, R&D and QC.

Nicky is an experienced scientist with expertise in insulin action and metabolic conditions. She has held postdoctoral roles with the Joslin Diabetes Centre at Harvard Medical School (Boston) and CSIRO (Parkville, Melbourne).

A professional Operations manager with extensive experience in implementation of project / quality and process improvements including with Hospira and Sigma Pharmaceuticals.

